Archives
-
In Vitro Drug Response Metrics in Cancer
2026-09-10
Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these readouts capture different contributions from proliferative arrest and cell death. The framework supports more informative, time-aware evaluation of anticancer responses and helps researchers avoid treating a single viability value as a complete measure of drug efficacy.
-
EZ Cap™ Cas9 mRNA (m1Ψ) Workflow
2026-09-10
Build a transient CRISPR-Cas9 workflow around Cap1-capped, m1Ψ-modified Cas9 mRNA for flexible genome editing in mammalian cells. This guide connects practical dosing, RNA handling, specificity testing, and nuclear-export biology to help researchers distinguish delivery problems from true editing limitations.
-
IPR-803 and Small-Molecule uPAR–uPA Inhibition
2026-09-09
The reference study established IPR-803 as a tractable small-molecule urokinase receptor inhibitor that disrupts the uPAR–uPA protein–protein interaction. By combining direct binding assays, cellular invasion models, pharmacokinetics, and a breast cancer metastasis model, it connected biochemical activity with an in vivo anti-metastatic outcome while also identifying important development limitations.
-
Cyanine 3 Tyramide for Cross-Species Brain Maps
2026-09-09
A thought-leadership guide to using Cyanine 3 Tyramide as a fluorescent dye for biomedical research, with mechanistic context for Tyramide Signal Amplification and a translational framework inspired by comparative claustrum gene-expression research.
-
MOG (35-55): A Mechanistic EAE Research Guide
2026-09-08
MOG (35-55) is a powerful myelin oligodendrocyte glycoprotein peptide for modeling EAE and multiple sclerosis biology. This guide connects peptide-driven disease induction with the STAT1/STAT2 interferon mechanism and translates that insight into practical assay decisions.
-
Alda 1: Reliable ALDH2 Assay Workflows
2026-09-08
This scenario-based guide explains how Alda 1 (SKU B5508) can strengthen ALDH2-focused viability, proliferation, cytotoxicity, and cardiac ischemia research workflows. It covers variant-aware experimental design, solvent and storage controls, interpretation of proliferation data, and practical criteria for selecting a reliable research reagent.
-
Necrostatin-1 RIP1 Kinase Inhibitor Workflows
2026-09-07
Build cleaner necroptosis experiments with Necrostatin-1, a selective RIP1 kinase inhibitor for pathway dissection, inflammatory injury models, and host–microbe studies. This guide connects practical dosing, assay controls, and troubleshooting to emerging evidence on bacterial T3SS-driven colitis.
-
Separating Growth Arrest from Cell Death in Cancer Assays
2026-09-07
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent dimensions of anticancer drug response. This framework helps researchers design assays and interpret dose–response data without treating reduced metabolic or proliferative output as direct evidence of cell killing.
-
Losartan Workflows for AT1 Signaling Research
2026-09-05
Losartan provides a practical, receptor-proximal way to dissect angiotensin II signaling, vascular smooth muscle behavior, and blood-pressure biology. This workflow-focused guide connects assay design, compound handling, quantitative readouts, and carefully bounded insights from diabetic nephropathy research.
-
2-Thio-dCTP Workflow for DNA Assays
2026-09-04
2-Thio-dCTP enables controlled incorporation of a sulfur-modified cytidine into DNA, supporting polymerase profiling, site-specific DNA modification, and DNA–protein interaction studies. This practical guide connects reagent handling with assay design inspired by new findings on SCP4, H3T3 dephosphorylation, and chromosome stability.
-
Selonsertib (GS-4997) for Renal Stress Models
2026-09-04
Selonsertib (GS-4997) enables selective interrogation of ASK1-driven oxidative stress, inflammation, and fibrosis in renal cell and animal models. This workflow translates lupus nephritis findings into practical assay design, dosing, controls, and troubleshooting strategies without treating preclinical evidence as clinical proof.
-
Homer1a–Caspase-6 Signaling in Inflammatory Pain
2026-09-03
The reference study identifies a Homer1a/caspase-6/tumor necrosis factor-alpha axis that links synaptic signaling, spinal microglial activation, and inflammatory pain hypersensitivity. Pharmacologic caspase-6 inhibition and lentiviral Homer1a overexpression produced convergent reductions in thermal hypersensitivity, supporting a mechanistic framework for studying nonapoptotic caspase signaling in the spinal dorsal horn.
-
Calnexin Shapes CFTR Variant Rescue
2026-09-03
A 2025 eLife study used deep mutational scanning to show that calnexin controls CFTR surface expression and corrector responsiveness in a variant-specific manner across 232 clinical variants. Its findings indicate that cellular proteostasis, not mutation identity alone, helps determine pharmacological rescue and should be incorporated into cystic fibrosis research and theratype design.
-
GnRH Antagonist Stereochemistry and Activity
2026-09-02
Samant and colleagues synthesized degarelix analogs containing racemic 3-(2-methoxy-5-pyridyl)-alanine at position 3, then resolved and assigned the resulting diastereomers. The D-configured analog retained nanomolar human GnRH receptor antagonism, whereas the L-configured counterpart was weaker and both compounds were short-acting in castrated male rats, highlighting the importance of stereochemistry and exposure in peptide design.
-
Staurosporine: Translational Logic for Kinase Biology
2026-09-02
A mechanistic and strategic guide to using Staurosporine as a broad-spectrum kinase tool for connecting kinase inhibition, apoptosis, angiogenesis, and translational cancer research while preserving causal discipline.